相似文献
1
Biomarker development in the precision medicine era: lung cancer as a case study.
Nat Rev Cancer. 2016 Aug;16(8):525-37. doi: 10.1038/nrc.2016.56. Epub 2016 Jul 8.
2
Pattern identification of lung cancer patients based on body constitution questionnaires (BCQ) and glycoproteomics for precision medicine.
Medicine (Baltimore). 2019 Jun;98(24):e16035. doi: 10.1097/MD.0000000000016035.
3
Exosomal Proteomics: Unveiling Novel Insights into Lung Cancer.
Aging Dis. 2024 Apr 9;16(2):876-900. doi: 10.14336/AD.2024.0409.
4
Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study.
BMC Cancer. 2023 Jun 13;23(1):540. doi: 10.1186/s12885-023-10997-x.
5
Molecular Imaging and Precision Medicine in Lung Cancer.
PET Clin. 2017 Jan;12(1):53-62. doi: 10.1016/j.cpet.2016.08.008. Epub 2016 Sep 10.
6
Advancing cancer drug development through precision medicine and innovative designs.
J Biopharm Stat. 2018;28(2):229-244. doi: 10.1080/10543406.2017.1402784. Epub 2017 Nov 27.
7
Application of spatial omics in gastric cancer.
Pathol Res Pract. 2024 Oct;262:155503. doi: 10.1016/j.prp.2024.155503. Epub 2024 Jul 30.
8
Biomarker Testing for Guiding Precision Medicine for Patients With Non-Small Cell Lung Cancer.
Chest. 2024 Nov;166(5):1239-1249. doi: 10.1016/j.chest.2024.08.006. Epub 2024 Aug 14.
9
Biomarkers in Non-Small Cell Lung Cancer: Perspectives of Individualized Targeted Therapy.
Anticancer Agents Med Chem. 2018;18(15):2070-2077. doi: 10.2174/1871520618666180827102101.
10
Epistemology, Ethics, and Progress in Precision Medicine.
Perspect Biol Med. 2016;59(3):293-310. doi: 10.1353/pbm.2016.0026.
引用本文的文献
1
A pan-cancer, pan-treatment model for predicting drug responses from patient-derived xenografts.
NAR Genom Bioinform. 2025 Aug 28;7(3):lqaf111. doi: 10.1093/nargab/lqaf111. eCollection 2025 Sep.
2
Precision Medicine for Cancer and Health Equity in Latin America: Generating Understanding for Policy and Health System Shaping.
Int J Environ Res Public Health. 2025 Aug 5;22(8):1220. doi: 10.3390/ijerph22081220.
3
Point-of-care mass spectrometry metabolomic analysis enabling intraoperative brain tumor diagnosis.
Theranostics. 2025 Jul 24;15(16):8137-8149. doi: 10.7150/thno.113336. eCollection 2025.
4
Mapping the future: bibliometric analysis of omics research trends in non-small cell lung cancer.
Discov Oncol. 2025 Aug 12;16(1):1536. doi: 10.1007/s12672-025-03140-8.
5
Next-Generation Sequencing (NGS) in non-small cell lung carcinoma: A real-world experience in the public health system of Galicia (Northwest Spain).
PLoS One. 2025 Jul 1;20(7):e0326336. doi: 10.1371/journal.pone.0326336. eCollection 2025.
6
City scale related to epidermal growth factor receptor mutations status in Chinese non-small cell lung cancer.
Discov Oncol. 2025 May 9;16(1):714. doi: 10.1007/s12672-025-02558-4.
7
Integrated Machine Learning Algorithms-Enhanced Predication for Cervical Cancer from Mass Spectrometry-Based Proteomics Data.
Bioengineering (Basel). 2025 Mar 9;12(3):269. doi: 10.3390/bioengineering12030269.
8
The Role of PLIN3 in Prognosis and Tumor-Associated Macrophage Infiltration: A Pan-Cancer Analysis.
J Inflamm Res. 2025 Mar 13;18:3757-3777. doi: 10.2147/JIR.S509245. eCollection 2025.
9
Pretrained transformers applied to clinical studies improve predictions of treatment efficacy and associated biomarkers.
Nat Commun. 2025 Mar 1;16(1):2101. doi: 10.1038/s41467-025-57181-2.
10
A quantitative prediction method utilizing whole omics data for biosensing.
Sci Rep. 2025 Jan 27;15(1):1928. doi: 10.1038/s41598-024-84323-1.
本文引用的文献
1
Indexed Pain Journals.
J Pain Palliat Care Pharmacother. 2008;22(1):45-46. doi: 10.1080/15360280801989377.
2
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.
Nat Genet. 2016 Jun;48(6):607-16. doi: 10.1038/ng.3564. Epub 2016 May 9.
3
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management. Preface.
Adv Exp Med Biol. 2016;890:v-vi.
4
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
Nat Rev Cancer. 2016 May;16(5):275-87. doi: 10.1038/nrc.2016.36. Epub 2016 Apr 15.
5
Long Noncoding RNAs in Cancer Pathways.
Cancer Cell. 2016 Apr 11;29(4):452-463. doi: 10.1016/j.ccell.2016.03.010.
6
Microbiome and Anticancer Immunosurveillance.
Cell. 2016 Apr 7;165(2):276-87. doi: 10.1016/j.cell.2016.03.001.
7
Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial.
Lancet Oncol. 2016 May;17(5):590-9. doi: 10.1016/S1470-2045(15)00621-X. Epub 2016 Mar 18.
8
Emerging applications of metabolomics in drug discovery and precision medicine.
Nat Rev Drug Discov. 2016 Jul;15(7):473-84. doi: 10.1038/nrd.2016.32. Epub 2016 Mar 11.
9
Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer.
J Thorac Oncol. 2016 Jul;11(7):976-88. doi: 10.1016/j.jtho.2016.02.015. Epub 2016 Mar 2.
10
Pulmonary nodules and CT screening: the past, present and future.
Thorax. 2016 Apr;71(4):367-75. doi: 10.1136/thoraxjnl-2015-208107. Epub 2016 Feb 26.
Zotero 插件